SymBio Pharmaceuticals

SymBio raises $24 million

Monday, March 7, 2011

Cephalon has joined with JAFCO, a Japanese private equity group, to put $24 million into SymBio Pharmaceuticals, a Japanese biotech studying its lead drug for non-Hodgkin’s lymphoma and multiple myeloma, according to Fierce Biotech. SymBio said it will use some of the Series E funding to in-license drugs for the Asian market.

[Read More]